Latest News for: cognate

Edit

The LpoA activator is required to stimulate the peptidoglycan polymerase activity of its cognate cell ...

PNAS 24 Aug 2021
These bifunctional enzymes possess both PG glycosyltransferase (PGT) and transpeptidase...
Edit

Worldwide Cell Therapy Manufacturing Industry to 2030 - Featuring Cognate BioServices, KBI Biopharma and Waisman Biomanufacturing Among Others

PR Newswire 11 Aug 2021
DUBLIN, Aug ... Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry ... Amongst other elements, the report includes ... 1 ... 5 ... Service Providers in North America8.2.1 Cognate BioServices8.2.1.1 ... 20.
Edit

Behind the Deal: This is why Charles River acquired Memphis-based Cognate BioServices

Business Journal 15 Apr 2021
Cognate’s revenue for 2021 is projected at $140 million with the potential to grow 25% annually over the next five years ... .
Edit

Charles River Laboratories Completes the Acquisition of Cognate BioServices

Business Wire 29 Mar 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River Laboratories completes the acquisition of Cognate BioServices ... .
Edit

Charles River Laboratories Completes the Acquisition of Cognate BioServices (Charles River Laboratories International Inc)

Public Technologies 29 Mar 2021
CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc ... Headquartered in Memphis, Tennessee, Cognate has operations in North America and Europe with over 500 employees ... Those risks and uncertainties include, but are not limited to, the ability to successfully integrate the acquisition of Cognate.
Edit

Weil Advises Charles River Labs on the Antitrust Aspects of its Pending Acquisition of Cognate BioServices (Weil, Gotshal & Manges LLP)

Public Technologies 02 Mar 2021
). March 01, 2021. Weil is advising Charles River Laboratories on the antitrust aspects of its pending acquisition of Cognate BioServices, a leading cell and gene therapy contract development and manufacturing organization ... Related Topics ... Disclaimer ... (noodl. 56552040) .
Edit

Charles River Laboratories $875 million acquisition of Cognate We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization (Davis Polk & Wardwell LLP)

Public Technologies 18 Feb 2021
Davis Polk is advising Charles River Laboratories International, Inc. in connection with its $875 million acquisition of Cognate BioServices, Inc ... Cognate is a dynamic, results-driven organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advanced cell therapy companies.
Edit

Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell ...

Business Wire 17 Feb 2021
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to acquire Cognate Bioservices ... .
Edit

Mass. bioscience giant to buy Memphis-based Cognate BioServices for $875M

Business Journal 17 Feb 2021
17 a definitive agreement to acquire Cognate BioServices Inc ... “Cognate BioServices presents a unique ...
Edit

Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development (Charles River Laboratories International Inc)

Public Technologies 17 Feb 2021
- Combines Cognate's Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CGMP Manufacturing - ... We look forward to welcoming Cognate's dedicated employees to the Charles River family,' Mr ... Cognate will be particularly synergistic with the Company's Biologics Testing Solutions business.
Edit

Cognate BioServices and Nucleus Biologics announce partnership in Cell and Gene Therapies

Johnson City Press 27 Jan 2021
27, 2021 /PRNewswire/ -- Cognate BioServices, Inc., the premier commercial-ready global CDMO in the Cell and Gene Therapy industry, and Nucleus Biologics, LLC, The Cell Performance Company™, announced today a partnership for custom and commercial medias and delivery systems for Cell and Gene Therapy clients ... About Cognate BioServices, Inc.
Edit

Cognate BioServices $212M local expansion underway, including $94M high-tech manufacturing investment

Business Journal 14 Jan 2021
“We are committed to furthering our business growth in the Mid-South and look forward to solidifying Memphis as a bioscience hub.” ... .
×